AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
514.04B
Market cap514.04B
Price-Earnings ratio
80.86
Price-Earnings ratio80.86
Dividend yield
2.39%
Dividend yield2.39%
Average volume
4.88M
Average volume4.88M
High today
$293.40
High today$293.40
Low today
$288.04
Low today$288.04
Open price
$291.00
Open price$291.00
Volume
4.32M
Volume4.32M
52 Week high
$293.40
52 Week high$293.40
52 Week low
$190.75
52 Week low$190.75

Stock Snapshot

The current AbbVie(ABBV) stock price is $293.40, with a market capitalization of 514.04B. The stock trades at a price-to-earnings (P/E) ratio of 80.86 and offers a dividend yield of 2.39%.

On 2026-10-29, AbbVie(ABBV) stock traded between a low of $288.04 and a high of $293.40. Shares are currently priced at $293.40, which is +1.9% above the low and 0.0% below the high.

AbbVie(ABBV) shares are trading with a volume of 4.32M, against a daily average of 4.88M.

During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $293.40 at its peak.

During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $293.40 at its peak.

ABBV News

Benzinga 3h
ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test - Benzinga

...

ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test - Benzinga
TipRanks 6h
AbbVie’s New Phase 1 ABBV-7828 Trial Signals Quiet Pipeline Expansion

Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has updated a new early stage trial called “A Phase 1, Single Ascending Dose S...

Simply Wall St 1d
AbbVie Files FDA Application For Etentamig In Multiple Myeloma

AbbVie (NYSE: ABBV) has submitted a Biologics License Application to the U.S. FDA for etentamig in relapsed or refractory multiple myeloma. The filing is backe...

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More ABBV News

24/7 Wall St. 1d
Why JEPI's Total Return Has Outpaced Its Payout

ETF Why JEPI’s Total Return Has Outpaced Its Payout JEPI's share price keeps climbing while its monthly cash payments quietly shrink, and the reason behind that...

Why JEPI's Total Return Has Outpaced Its Payout
24/7 Wall St. 1d
Retire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever

Investing Retire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever Treasury yields near 5% make dividend stocks work harder to justify th...

Retire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever
Zacks 2d
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie

Chicago, IL – October 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
Zacks 2d
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings

AbbVie (ABBV Quick QuoteABBV - Free Report) is set to report third-quarter 2026 earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate...

Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
Simply Wall St 5d
Can AbbVie Still Be A Bargain After Trial Wins?

AbbVie has delivered a powerful run over the past few years, so the obvious question now is whether today's US$285.64 price still lines up with the cash the bus...

TipRanks 6d
FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi for Crohn’s

AbbVie (ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous induction regimen for Skyrizi for adults with moderately to severely a...

24/7 Wall St. 6d
Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different

Investing Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different Treasury yields have turned dividend investing into a minefield, but five...

Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.